EN DE
Watch aap Implantate AG for free: we tell you when fair value or trend changes.
Data-driven stock valuation

aap Implantate AG (AAQ1) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of aap Implantate AG stock €1.25, price €1.35, that is 7.4% below the price, quality 38 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare DE · ISIN DE000A3H2101

AI aap Implantate AG logo Thin data Nov 16, 2026

aap Implantate AG

AAQ1 · XETRA

Rising price, but the stock is already about fairly priced and weak company: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Low debt 
Fair value €1.25 · Fairly valued 
Expensive Growth (revenue 5y +6.0 %/yr in EUR) 
Quality 38/100 
Loss-making · -22.4% net margin (TTM) 
Negative free cash flow 
Trails peers (3/11) 
Narrow moat 15/100 · thin data
Thin data 
Estimate⚠ Thinly traded
Watch aap Implantate AG for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€4.70 €0.7300 Fair Value €1.25 Jun 2020 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range €0.7300 – €4.70 · fair‑value band €0.9400 – €1.56 · the €1.35 price screens above the €1.25 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow aap Implantate in your weekly email

Every Wednesday you see whether aap Implantate is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

aap Implantate AG develops, manufactures, and markets traumatology products for orthopedics in Germany and internationally. The company offers LOQTEQ, an anatomical plating system for the treatment of ankle, straight plates, knee, elbow, wrist, and shoulder.

Show moreShow less

It also provides hole screws and Repro Bone materials. The company sells its products directly to hospitals, purchasing groups, and hospital groups through a network of distributors. aap Implantate AG was founded in 1990 and is headquartered in Berlin, Germany.

Stock analysis

aap Implantate AG (AAQ1) currently trades at €1.35, while our estimate is €1.25, so the stock looks roughly fairly valued today (gap 8.0%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: €0.9400 (bear) to €1.56 (bull), the price of €1.35 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

aap Implantate AG reported revenue of €12.5M in FY2025 versus €12.2M in FY2021, a compound +0.7%/yr. Reported net income was −€2.6M in FY2025.

Key figures

Market cap €19.5M Micro · P/S ratio 1.71 · EPS (TTM) €−0.2000 · Net margin −22.4% · Return on equity −31.1% · Return on assets (EBIT) −19.2% (5-year average) · Operating margin −17.3% · Revenue (TTM) €12.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).

What moves the price

The share trades about 37% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −16% fair-value upside, at −7%, AAQ1 screens cheaper than that median.

Fair Value

Bear €0.9400 Fair Value €1.25 Bull €1.56
Price €1.35 · Downside -7.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 33
How much profit the company makes from its sales and capital
Quality Growth 51
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 53
Debt, balance sheet and risk of trouble
Investment 93
Does it invest with discipline instead of growing at any price?
Low Volatility 62
How calm the share price moves, does not count
Price momentum 26
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 19
Distance to the 52-week high, does not count
New shares 21
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 25/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+2.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.0%
Start year 2020 (pandemic). Over 10 years: +0.2% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−89.5% (2020) → −20.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch AAQ1, get fair value alerts →

Compare aap Implantate AG with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Below median
Fair Value upside −7.4% · Above median
Profitability
Return on assets −18.9% · Below median
Net margin (12 months) −22.4% · Below median
Operating margin (12 months) −17.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −4.5% · Bottom 25%
Balance sheet
Debt / equity 0.00× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 2.24× · Pricier than median
P/S (12 months) 1.60× · Cheaper than median
PEG 29.43× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)23 · sector 17
FUTURE (revenue growth)0 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
DexCom, Inc DXCM $81.61 $91.66 +12% vs AAQ1
Boston Scientific Corporation BSX $43.69 $48.77 +12% vs AAQ1
Stryker Corporation SYK $310.72 $340.60 +10% vs AAQ1
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥184.30 ¥197.34 +7% vs AAQ1
GE HealthCare Technologies Inc GEHC $82.96 $69.92 −16% vs AAQ1
Siemens Healthineers AG SHL €44.00 €34.51 −22% vs AAQ1
Edwards Lifesciences Corporation EW $107.11 $81.94 −24% vs AAQ1
Medtronic plc MDT $102.88 $74.89 −27% vs AAQ1
Abbott Laboratories, ABT $107.45 $75.28 −30% vs AAQ1
Koninklijke Philips N.V PHIA €27.54 €15.23 −45% vs AAQ1

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

aap Implantate AG: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "aap Implantate AG Fair Value". https://www.fairvalue-calculator.com/stock/AAQ1

Frequently asked questions

Is aap Implantate AG (AAQ1) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is €1.25 versus a price of €1.35, about 7% lower (fairly valued).
What is the fair value of AAQ1?
Our estimate for aap Implantate AG is €1.25 (as of Nov 16, 2026), built from audited fundamentals. The current price: €1.35.
What is the quality score of AAQ1?
aap Implantate AG has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for aap Implantate AG (AAQ1)?
Our calculated price target is the estimate of €1.25 (as of Nov 16, 2026). Cautious scenario €0.9400, optimistic scenario €1.56. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the aap Implantate AG stock forecast for 2026?
Our estimate puts fair value at €1.25, about 7% lower versus a price of €1.35 (fairly valued). Cautious scenario €0.9400, optimistic scenario €1.56. The calculation is refreshed regularly with new filings.
What is the revenue of aap Implantate AG (AAQ1)?
aap Implantate AG reported trailing-twelve-month revenue of about €12.2M (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of aap Implantate AG (AAQ1)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For aap Implantate AG it is €1.25 per share (as of Nov 16, 2026), against a price of €1.35.
Is aap Implantate AG stock overvalued or undervalued in 2026?
As of Nov 16, 2026, AAQ1 trades above its calculated fair value: price €1.35, fair value €1.25, a gap of about −7% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AAQ1?
No. The price is what the market pays today (€1.35); the fair value is what the company's own numbers justify (€1.25). For aap Implantate AG the two are €0.1000 per share apart. That gap is exactly why we show both numbers side by side.
How much is aap Implantate AG worth?
The market values aap Implantate AG at about €19.5M (market capitalisation, as of Nov 16, 2026). Per share that is €1.35; our models calculate a fair value of €1.25 per share.
What do the bullish and bearish scenarios say about AAQ1?
Our models span a range for aap Implantate AG: cautious scenario €0.9400, base €1.25, optimistic €1.56 per share (as of Nov 16, 2026, price €1.35). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of AAQ1?
The PEG ratio of aap Implantate AG is 29.43 (P/E divided by earnings growth, as of Nov 16, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of aap Implantate AG (AAQ1)?
Balance-sheet figures for aap Implantate AG (as of Nov 16, 2026): return on equity −31.1%, debt of 0.00 per unit of equity (balance sheet 30 Jun 2026). They feed the Quality Score of 38/100, which uses the fiscal-year figures and measures business quality independently of the share price.
How far is AAQ1 from its 52-week high?
aap Implantate AG trades at €1.35, about 37% below its 52-week high of €2.14 and 7% above the low of €1.26 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of €1.25 is for.
Which stocks are comparable to aap Implantate AG?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is aap Implantate AG stock attractive at the current price?
The data as of Nov 16, 2026: price €1.35, calculated fair value €1.25 (−7%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. aap Implantate AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of aap Implantate AG (AAQ1)?
The closing price on Nov 16, 2026 was €1.35. Our estimate is €1.25, about 7% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with aap Implantate AG right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of aap Implantate AG

How large is the market capitalisation of aap Implantate AG (AAQ1)?
The market capitalisation of aap Implantate AG is €19.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of aap Implantate AG (AAQ1)?
The price-to-sales ratio of aap Implantate AG is 1.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of aap Implantate AG (AAQ1)?
Earnings per share at aap Implantate AG are €−0.2000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of aap Implantate AG (AAQ1)?
The net margin of aap Implantate AG is −22.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of aap Implantate AG (AAQ1)?
The return on equity (ROE) of aap Implantate AG is −31.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of aap Implantate AG (AAQ1)?
On an EBIT basis the return on assets of aap Implantate AG is −19.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of aap Implantate AG (AAQ1)?
The operating margin of aap Implantate AG is −17.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at aap Implantate AG (AAQ1)?
Revenue at aap Implantate AG is down 4.5% versus a year earlier (3y avg +2.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does aap Implantate AG (AAQ1) generate?
The free cash flow of aap Implantate AG is −€2.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does aap Implantate AG (AAQ1) carry?
The net debt of aap Implantate AG is €3.7M (balance sheet 30 Jun 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch aap Implantate AG in the live analysis

One click puts aap Implantate AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.